Autopsy report · NCT04536077

Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Celldex decision”

The sponsor’s own words in the registry.

Life of this trial

Registered 1 year before it started.
Ran for about 2 years 3 months before it stopped.
16 participants enrolled.
Results were posted on the registry 11 months after it ended.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: Washington University School of Medicine
Sponsor type: University, hospital or other
Conditions: Pancreatic Cancer; Cancer of the Pancreas; Pancreas Cancer
Interventions: CDX-301; CDX-1140; Research blood draw
Participants: 16
Sites: 1
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.